Contraception-Pipeline Review, H1 2015

Contraception-Pipeline Review, H1 2015

  • Products Id :- GMDHC6592IDB
  • |
  • Pages: 87
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Contraception-Pipeline Review, H1 2015


Global Markets Direct's, 'Contraception-Pipeline Review, H1 2015', provides an overview of the Contraception's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Contraception

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Contraception

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Contraception Overview 9

Therapeutics Development 10

Pipeline Products for Contraception-Overview 10

Pipeline Products for Contraception-Comparative Analysis 11

Contraception-Therapeutics under Development by Companies 12

Contraception-Therapeutics under Investigation by Universities/Institutes 14

Contraception-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Contraception-Products under Development by Companies 19

Contraception-Products under Investigation by Universities/Institutes 21

Contraception-Companies Involved in Therapeutics Development 22

Actavis plc 22

Agile Therapeutics, Inc. 23

ANI Pharmaceuticals, Inc. 24

Antares Pharma, Inc. 25

Evofem, Inc. 26

Hydra Biosciences, Inc. 27

Intas Pharmaceuticals Ltd. 28

Ligand Pharmaceuticals, Inc. 29

Merck & Co., Inc. 30

Orbis Biosciences, Inc. 31

Pantarhei Bioscience BV 32

Teva Pharmaceutical Industries Limited 33

Contraception-Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Combination Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

(ethinyl estradiol + levonorgestrel)-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

(ethinylestradiol + levonorgestrel)-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

(nestorone + estradiol)-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

(prasterone + estradiol + progesterone)-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

AG-200 ER-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AG-200 SP-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Amphora-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

esterol-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

etonogestrel-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

EVE-106-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

levonorgestrel-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

LJ-102-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

MK-8342B-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Monoclonal Antibody Conjugates for Contraception-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

norethindrone-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

S-003296-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

S-0101255-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecule 1 for Fertility Control-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecule 2 for Fertility Control-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Small Molecule to Modulate Progesterone Receptor for Fertility Control-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecules to Block CatSper1 Ion Channel for Contraception-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Synthetic Peptides for Contraception-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

tanaproget-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

ulipristal acetate-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Contraception-Recent Pipeline Updates 73

Contraception-Dormant Projects 77

Contraception-Discontinued Products 79

Contraception-Product Development Milestones 80

Featured News & Press Releases 80

Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora 80

Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch 80

Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study 80

Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla 81

Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion 82

Jul 04, 2014: Teva Receives CHMP Positive Opinion for Seasonique Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries 82

Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date 83

Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device 83

Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora Non-hormonal Contraceptive Gel 84

Jul 23, 2013: Enrollment Completed for Evofem's 3,200-subject Global Trial of Amphora Non-hormonal Contraceptive Gel 84

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 86

Disclaimer 87

List of Tables

Number of Products under Development for Contraception, H1 2015 10

Number of Products under Development for Contraception-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Contraception-Pipeline by Actavis plc, H1 2015 22

Contraception-Pipeline by Agile Therapeutics, Inc., H1 2015 23

Contraception-Pipeline by ANI Pharmaceuticals, Inc., H1 2015 24

Contraception-Pipeline by Antares Pharma, Inc., H1 2015 25

Contraception-Pipeline by Evofem, Inc., H1 2015 26

Contraception-Pipeline by Hydra Biosciences, Inc., H1 2015 27

Contraception-Pipeline by Intas Pharmaceuticals Ltd., H1 2015 28

Contraception-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 29

Contraception-Pipeline by Merck & Co., Inc., H1 2015 30

Contraception-Pipeline by Orbis Biosciences, Inc., H1 2015 31

Contraception-Pipeline by Pantarhei Bioscience BV, H1 2015 32

Contraception-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 33

Assessment by Monotherapy Products, H1 2015 34

Assessment by Combination Products, H1 2015 35

Number of Products by Stage and Target, H1 2015 37

Number of Products by Stage and Mechanism of Action, H1 2015 39

Number of Products by Stage and Route of Administration, H1 2015 41

Number of Products by Stage and Molecule Type, H1 2015 43

Contraception Therapeutics-Recent Pipeline Updates, H1 2015 73

Contraception-Dormant Projects, H1 2015 77

Contraception-Dormant Projects (Contd..1), H1 2015 78

Contraception-Discontinued Products, H1 2015 79

List of Figures

Number of Products under Development for Contraception, H1 2015 10

Number of Products under Development for Contraception-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 34

Assessment by Combination Products, H1 2015 35

Number of Products by Top 10 Targets, H1 2015 36

Number of Products by Stage and Top 10 Targets, H1 2015 37

Number of Products by Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Top 10 Routes of Administration, H1 2015 40

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 41

Number of Products by Top 10 Molecule Types, H1 2015 42

Number of Products by Stage and Top 10 Molecule Types, H1 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Actavis plc

Agile Therapeutics, Inc.

ANI Pharmaceuticals, Inc.

Antares Pharma, Inc.

Evofem, Inc.

Hydra Biosciences, Inc.

Intas Pharmaceuticals Ltd.

Ligand Pharmaceuticals, Inc.

Merck & Co., Inc.

Orbis Biosciences, Inc.

Pantarhei Bioscience BV

Teva Pharmaceutical Industries Limited

Contraception Therapeutic Products under Development, Key Players in Contraception Therapeutics, Contraception Pipeline Overview, Contraception Pipeline, Contraception Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]